
A small, early trial demonstrated that a combination of Imlygic and Keytruda can have clinical benefit for patients with advanced melanoma.
A small, early trial demonstrated that a combination of Imlygic and Keytruda can have clinical benefit for patients with advanced melanoma.
While inherited factors do play a role in many people getting colorectal cancer, researchers are still unsure how to identify these mutations.
Published: June 13th 2016 | Updated:
Published: June 16th 2016 | Updated: